trofinetide · Acadia Pharms Inc · NDA 219884

Daybue Stix

Earliest generic entry, as listed · earliest of 3 marketed strengths
12 Jan 2043

Blocked by patent: US 11827600 (pediatric extension), US 12492167 (pediatric extension).

Listed patents · 4 unexpired

8 Orange Book listing rows for 4 patents, including 4 pediatric extensions. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.

PatentClaimsExpires
US 11827600drug substance, drug product, use U-355612 Jan 2043
US 11827600 listing rowdrug substance, drug product, use U-355612 Jul 2042
US 11827600 listing rowpediatric extension · sets the listed date12 Jan 2043
US 12492167drug substance, drug product, use U-355612 Jan 2043
US 12492167 listing rowdrug substance, drug product, use U-355612 Jul 2042
US 12492167 listing rowpediatric extension · sets the listed date12 Jan 2043
US 11370755drug substance, drug product3 Feb 2041
US 11370755 listing rowdrug substance, drug product3 Aug 2040
US 11370755 listing rowpediatric extension3 Feb 2041
US 9212204use U-355627 Jul 2032
US 9212204 listing rowuse U-355627 Jan 2032
US 9212204 listing rowpediatric extension27 Jul 2032

Exclusivities · 3 unexpired

PEDpediatric (6 months added)10 Sep 2030
ODE*10 Mar 2030
PEDpediatric (6 months added)10 Sep 2028
NCEnew chemical entity (5 years)10 Mar 2028

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 3

NDA · productFormStrengthListed expiry
219884 · 001 · RLDfor solution, oral5000MG/PACKET12 Jan 2043
219884 · 002 · RLDfor solution, oral6000MG/PACKET12 Jan 2043
219884 · 003 · RLDfor solution, oral8000MG/PACKET12 Jan 2043